SCHEDULE 13D/A: Fortress Biotech Divests Checkpoint Therapeutics Stake Following Merger Completion

Fortress Biotech, Inc. has ceased to be a beneficial owner of Checkpoint Therapeutics, Inc. common stock following the latter's merger with a subsidiary of Sun Pharmaceutical Industries, Inc.

Summary

• Fortress Biotech, Inc. (the "Reporting Person") has filed Amendment No. 11 to its Schedule 13D, reporting a significant change in its beneficial ownership of Checkpoint Therapeutics, Inc. (the "Issuer").
• On May 30, 2025 (the "Closing Date"), Checkpoint Therapeutics, Inc. completed its merger (the "Merger") with Snoopy Merger Sub, Inc., a wholly-owned subsidiary of Sun Pharmaceutical Industries, Inc. ("Parent").
• As a result of the Merger, Checkpoint Therapeutics, Inc. is now a wholly-owned subsidiary of Sun Pharmaceutical Industries, Inc.
• Each issued and outstanding share of Checkpoint Therapeutics capital stock, including those previously held by Fortress Biotech, was automatically canceled.
• Shareholders received $4.10 in cash per share and one non-tradable contingent value right (CVR) representing the right to receive up to $0.70 upon the achievement of a specified milestone.
• Fortress Biotech, Inc. no longer beneficially owns any shares of Checkpoint Therapeutics' common stock or Class A common stock.
• Prior to the Merger, Fortress Biotech transferred 100,000 shares of Checkpoint Therapeutics common stock to its Chairman, President, and CEO, Lindsay A. Rosenwald, M.D., and Executive Vice Chairman, Michael S. Weiss, upon their exercise of previously outstanding warrants.

Sentiment

Score: 6

Explanation: The document is factual, reporting the completion of a merger and the resulting change in beneficial ownership. For the reporting person (Fortress Biotech), it represents a monetization event, which is generally positive, though the CVR introduces some contingency.

Positives

• Fortress Biotech, as a former shareholder, received a cash payment of $4.10 per share for its Checkpoint Therapeutics holdings, providing liquidity.
• The potential to receive an additional $0.70 per share via a contingent value right (CVR) offers further upside if a specified milestone is achieved.

Negatives

• Fortress Biotech no longer holds any equity interest in Checkpoint Therapeutics, losing potential future upside from the company's operations beyond the CVR.
• The contingent value right (CVR) payment of up to $0.70 is non-tradable and dependent on the achievement of a specified milestone, introducing uncertainty regarding its realization.

Risks

• The contingent value right (CVR) payment of up to $0.70 is not guaranteed and is dependent on the achievement of a specified milestone, which may or may not occur.

Future Outlook

The document primarily reports a completed transaction and the resulting change in beneficial ownership. It does not provide forward-looking statements or guidance regarding the future operations of the merged entity or Fortress Biotech's strategic direction post-divestment.

Industry Context

This filing details the completion of an acquisition in the biotechnology sector, where a smaller company (Checkpoint Therapeutics) was acquired by a larger pharmaceutical entity (Sun Pharmaceutical Industries). Such M&A activities are common in the biotech industry, driven by strategic portfolio expansion, access to new drug candidates, or market consolidation.

Related Party Transactions

• Fortress Biotech transferred 100,000 shares of Checkpoint Therapeutics common stock to its Chairman, President and Chief Executive Officer, Lindsay A. Rosenwald, M.D., and its Executive Vice Chairman, Michael S. Weiss, upon their exercise of previously outstanding warrants.

Stakeholder Impact

• Shareholders of Checkpoint Therapeutics, including Fortress Biotech, received cash and contingent value rights for their shares, converting their equity into a defined payout.
• Checkpoint Therapeutics employees and operations are now part of Sun Pharmaceutical Industries, Inc., potentially leading to integration and operational changes.

Key Dates

Keywords

Checkpoint Therapeutics, Fortress Biotech, Sun Pharmaceutical Industries, Merger, Acquisition, Schedule 13D, Beneficial Ownership, Contingent Value Right, CVR, Common Stock